drugset
drugset / Trial / NCT05378269

Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA

NCT05378269 ↗

Phase 1/2 Completed 17 enrolled Daré Bioscience, Inc.
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of the study is to study the safety, PK and PD of Intravaginal Tamoxifen on postmenopausal women with vulvar vaginal atrophy.

Timeline

Start
2021-11-22
Primary completion
2022-12-20
Completion
2023-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamoxifen Small molecule 1 mg Other
Subject Tamoxifen Small molecule 5 mg Other
Subject Tamoxifen Small molecule 10 mg Other
Subject Tamoxifen Small molecule 20 mg Other

Indications

skin atrophy